@Article{Niknafs_Han_Ma-The_lncRN_lands-2016,
  author =	 {Niknafs, Yashar S. and Han, Sumin and Ma, Teng and Speers, 
                  Corey and Zhang, Chao and Wilder-Romans, Kari and Iyer, 
                  Matthew K. and Pitchiaya, Sethuramasundaram and Malik, Rohit 
                  and Hosono, Yasuyuki and Prensner, John R. and Poliakov, 
                  Anton and Singhal, Udit and Xiao, Lanbo and Kregel, Steven 
                  and Siebenaler, Ronald F. and Zhao, Shuang G. and Uhl, 
                  Michael and Gawronski, Alexander and Hayes, Daniel F. and 
                  Pierce, Lori J. and Cao, Xuhong and Collins, Colin and 
                  Backofen, Rolf and Sahinalp, Cenk S. and Rae, James M. and 
                  Chinnaiyan, Arul M. and Feng, Felix Y.},
  title =	 {The {lncRNA} landscape of breast cancer reveals a role for 
                  {DSCAM}-{AS1} in breast cancer progression},
  journal =	 {Nat Commun},
  year =	 {2016},
  volume =	 {7},
  number =	 {},
  pages =	 {12791},
  user =	 {wrightp},
  pmid =	 {27666543},
  doi = 	 {10.1038/ncomms12791},
  issn = 	 {2041-1723},
  abstract =	 {Molecular classification of cancers into subtypes has 
                  resulted in an advance in our understanding of tumour 
                  biology and treatment response across multiple tumour types. 
                  However, to date, cancer profiling has largely focused on 
                  protein-coding genes, which comprise <1% of the genome. Here 
                  we leverage a compendium of 58,648 long noncoding RNAs 
                  (lncRNAs) to subtype 947 breast cancer samples. We show that 
                  lncRNA-based profiling categorizes breast tumours by their 
                  known molecular subtypes in breast cancer. We identify a 
                  cohort of breast cancer-associated and oestrogen-regulated 
                  lncRNAs, and investigate the role of the top prioritized 
                  oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1. We 
                  demonstrate that DSCAM-AS1 mediates tumour progression and 
                  tamoxifen resistance and identify hnRNPL as an interacting 
                  protein involved in the mechanism of DSCAM-AS1 action. By 
                  highlighting the role of DSCAM-AS1 in breast cancer biology 
                  and treatment resistance, this study provides insight into 
                  the potential clinical implications of lncRNAs in breast 
                  cancer.}
}